June 2013 Editor's Picks: Products from Brabender Pharma and K-Tron - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

June 2013 Editor's Picks: Products from Brabender Pharma and K-Tron

Equipment and Processing Report

Featured products from Pharmaceutical Technology's monthly newsletter, Equipment & Processing Report

Brabender Pharma
Tabletop twin-screw extruder features easy cleaning.

Brabender Pharma’s PTSE 12/36 EC tabletop, 12-mm pharmaceutical twin-screw extruder is suitable for hot-melt extrusion (HME), early formulation development, and preparation of samples for clinical studies. The more compact addition to the company’s product line enhances the ability to address the challenges of HME in feasibility studies. The extruder has a removable barrel liner and a horizontally split barrel to allow quick access and ease of cleaning and sterilization. Two additional openings can be used as downstream feeding or venting ports. Segmented screws can be configured to customer specifications and optional ports can be added on request.


K-Tron
Micro-ingredient feeder has high accuracy for low feedrates.

K-Tron’s low-rate, micro-ingredient feeder line now includes the MT16 with a 16-mm feed screw and a overall feedrate capacity of 0.02 dm³/hr to 27 dm³/hr. The feeder is ideal for applications feeding high-value additives or APIs in pharmaceutical processes that require a high degree of accuracy. The unit can be used with the MT12-mm and MT16-mm twin-screw or single-screw feeder modules. The interchangeable screws provide versatility to handle a broad range of materials. The unit has a smaller overall profile and footprint that allows for closer discharge dimensions and is ideal for multi-ingredient cluster arrangements. The design also allows for extended screw profiles. The unit is easy to take apart, clean, and maintain with a totally enclosed weight sensor.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: Equipment and Processing Report,
Click here